Leading pharma companies have pitched into Sofinnova Partners’ new accelerator fund, which has exceeded the target and closed at €165 million (US$180 million). In what is said to be the largest pan-European biotech accelerator fund, Amgen Inc., Bristol Myers Squibb Co. and Pfizer Ventures will get an inside track on startups formed around academic research, as the nascent companies are shaped up for formal investment rounds.
Wall Street was weighing the gravity of the death from acute liver failure of a patient who was treated for Duchenne muscular dystrophy (DMD) with Sarepta Therapeutics Inc.’s gene therapy, Elevidys (delandistrogene moxeparvovec). Liver injury is a known possible side effect of the product, first approved by the U.S. FDA in June 2023 for DMD, as well as other AAV-mediated gene therapies, and the potential problem is highlighted in Elevidys’ prescribing information.
Maxion Therapeutics Ltd. is poised to extend the therapeutic reach of antibodies into the vast field of G-protein coupled receptors and ion channel targets, after raising $72 million in a series A round.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Ani, BMS, Innovent, Korro.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Acelyrin, Alumis, Azurity, Basilea, Eton, Covis, Medexus, NX Development, Pfizer, Sutro.
RSS
